oxaprozin also known oxaprozinum nonsteroidal antiinflammatory drug used relieve inflammation swelling stiffness joint pain associated osteoarthritis rheumatoid arthritis chemically propionic acid derivative safety efficacy established children years juvenile rheumatoid arthritis increased risk adverse reactions elderly population patented approved medical use oxaprozin one twenty nsaids included clinical trial compare efficacy nsaids shortterm treatment ankylosing spondylitis nsaids compared completing randomized controlled trials nsaids patients active efficacy reported weeks adverse effects examined efficacy measured change pain score change duration morning stiffness total trials total participants completed trials fewer participants nsaids found reduce pain placebo found significantly better regards decrease morning stiffness likelihood adverse events significant difference nsaids concluded etoricoxib effective reducing pain however due small studies insufficient evidence one nsaid could determined effective treatment etoricoxib patients taking oxaprozin experienced least amount pain fewer adverse effects october us food drug administration fda required drug label updated nonsteroidal antiinflammatory medications describe risk kidney problems unborn babies result low amniotic recommend avoiding nsaids pregnant women weeks later oxaprozin developed patented us patent oxazoles filed november published may following filing patent first description oxaprozin exhibiting antiinflammatory properties outlined article diaryloxazole diaylthiazolealkanoci acids two novel series nonsteroidal antiinflammatory agents article published nature december wyethayerst licensed marketing rights us canada puerto rico caribbean daypro became available january upon release pink sheet estimated average whole sale price searles daypro mg price comparable prescription nsaids oxaprozin new drug application nda submitted fda august drug granted nda day review june searle agreed complete seven phase iv postmarketing studies october fda approved daypro october since approval daypro searle companies submitted abbreviated new drug applications andas fda daypro searle listed reference listed drug prove bioequivalence andas table listing approved oxaprozin products advantage dose llc recalled oxaprozin tablets november company conformance cgmp recall httpsenwikipediaorgwikioxaprozin